A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
Completed · Phase 1
Conditions studied: HIV Infections
In brief
To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive adult patients.
Key facts
- Study ID
- NCT00001992
- Run by
- Genentech, Inc.
- Last updated by the study team
- 2005-06-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must have the following:
- Stage 1 or 2 Walter Reed clinical staging of HIV infected individuals.
- The ability to understand and sign a written informed consent form, which must be obtained prior to study entry.
- Be available for 24 weeks so that follow up may be completed.
- Qualify for care as Department of Defense health care beneficiary.
You may not qualify if…
- Co-existing Condition:
- Patients with the following conditions or symptoms are excluded:
- Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results.
- Concurrent Medication:
- Excluded:
- Corticosteroids or other known immunosuppressive drugs.
- Any experimental agents.
- Patients with the following are excluded:
- Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results.
- Prior Medication:
- Excluded within 30 days of study entry:
- Zidovudine or other anti-retroviral agents.
Where it is running
- Walter Reed Army Institute of Research — Rockville, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.